Abstract
In this paper, we discuss the role of particle therapy—a novel radiation therapy (RT) that has shown rapid progress and widespread use in recent years—in multidisciplinary treatment. Three types of particle therapies are currently used for cancer treatment: proton beam therapy (PBT), carbon-ion beam therapy (CIBT), and boron neutron capture therapy (BNCT). PBT and CIBT have been reported to have excellent therapeutic results owing to the physical characteristics of their Bragg peaks. Variable drug therapies, such as chemotherapy, hormone therapy, and immunotherapy, are combined in various treatment strategies, and treatment effects have been improved. BNCT has a high dose concentration for cancer in terms of nuclear reactions with boron. BNCT is a next-generation RT that can achieve cancer cell-selective therapeutic effects, and its effectiveness strongly depends on the selective 10B accumulation in cancer cells by concomitant boron preparation. Therefore, drug delivery research, including nanoparticles, is highly desirable. In this review, we introduce both clinical and basic aspects of particle beam therapy from the perspective of multidisciplinary treatment, which is expected to expand further in the future.
Highlights
We initially reported the usefulness of proton beam therapy (PBT) alone or a PBT boost following photon radiation therapy (RT) without concurrent chemotherapy for patients with unresectable esophageal cancer [36]
androgen deprivation therapy (ADT) is combined with carbon-ion beam therapy (CIBT) for 2–6 months in intermediate-risk Prostate cancer (PC) patients and for 2 years in high-risk PC patients based on previous phase I/II and II clinical trials; the appropriate indication criteria and duration of ADT use for PC in combination with high-dose RT, including PBT and CIBT, remains unknown
Owing to its multifunctional role and low expression in normal cells, Hsp90 inhibitors are considered a good target for cancer therapy; there are few reports on its effects in combination with particle therapy, and we found two reports on its combination with carbon beams [105,106]. 17AAG enhanced the cytotoxic effect on lung cancer cells and the antitumor effect on lung cancer transplanted tumors after C-ions to the same extent as X-rays [105]
Summary
Yoshitaka Matsumoto 1,2, * , Nobuyoshi Fukumitsu 3 , Hitoshi Ishikawa 4 , Kei Nakai 1,2. Proton Medical Research Center, University of Tsukuba Hospital, Tsukuba 305-8576, Japan
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
